[Trimetazidine in correction of chronic heart failure in patients with ischemic heart disease].
Twenty patients with NYHA class II-IV heart failure and ejection fraction below 40% received standard therapy (control period) or standard therapy plus open trimetazidine (20 mg t.i.d.) for 3 months in a cross-over design. Therapy with trimetazidine was associated with attenuation of clinical signs of heart failure (average NYHA class 2.90-/+0.10, 2.27-/+0.20 and 2.88-/+0.13, p<0.05, at baseline, after trimetazidine and control period, respectively), improvement of results of 6-minute walk test (average distance 321-/+19, 375-/+20 m, p<0.02, and 303-/+17 m at baseline, after trimetazidine and control period, respectively), increase of left ventricular ejection fraction (from 34.1-/+2.0 to 38.1-/+1.8%, p<0.05) and improvement of quality of life. Thus in patients with heart failure addition of trimetazidine to standard therapy for 3 months produced positive effect on clinical and hemodynamic status, exercise tolerance and quality of life.
Nedoshivin
A O
AO
Kutuzova
A E
AE
Nesterova
I V
IV
Mikhaĭlova
I E
IE
Rubashkina
E I
EI
Novikova
N A
NA
Liasnikova
E A
EA
Perepech
N B
NB
D002908:Chronic Disease; D003430:Cross-Sectional Studies; D006801:Humans; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy*; D011446:Prospective Studies; D012720:Severity of Illness Index; D014292:Trimetazidine / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D014665:Vasodilator Agents; D014292:Trimetazidine